The course of immunotherapy for liver cancer varies depending on the patient’s condition and the symptoms of the disease, and there are no strict requirements. The role of the immune system is to detect and destroy tumor cells, which can control the disease. However, some tumors may take advantage of the defects of the immune system and avoid the attack of the immune system, thus not being eliminated. Therefore, “treating” the immune system and regulating its tumor-killing function can reduce tumor recurrence and metastasis and achieve the therapeutic purpose. For advanced liver cancer, chemotherapy, intervention, radiotherapy, targeted therapy and immunotherapy are the main treatment methods at present. Among them, PD-1 inhibitors are the latest immunotherapy drugs, commonly used drugs such as karelizumab and tirilizumab. According to some studies, the 1-year overall survival rate of patients with inoperable advanced hepatocellular carcinoma treated with carelizumab monotherapy is about 56%; and the 1-year overall survival rate of patients with unresectable hepatocellular carcinoma treated with tirilizumab who have received at least one type of systemic therapy in the past is about 52%. According to the drug insert, tirilizumab is administered by intravenous infusion at a recommended dose of 200 mg every 3 weeks. The drug is administered until disease progression or intolerable toxicity occurs. Liver cancer patients are advised to go to regular hospitals for evaluation of their condition and follow the doctor’s instructions to actively cooperate with the treatment in order to improve the quality of life and prolong the survival period. Drug treatment should be carried out under the guidance of professional doctors, do not use drugs by yourself.